BMO Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Jazz Pharmaceuticals (JAZZ), with a price target of $206. The company’s shares closed yesterday at $127.76.

According to TipRanks.com, Nachman is a 2-star analyst with an average return of 1.0% and a 45.5% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aquestive Therapeutics Inc, and SAGE Therapeutics.

Jazz Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $177.38, a 38.8% upside from current levels. In a report issued on February 12, Oppenheimer also maintained a Buy rating on the stock with a $175 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $184 and a one-year low of $113.52. Currently, Jazz Pharmaceuticals has an average volume of 710K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.